Medical News

RSS

Potential risk factors in skipping insulin injections

More than half of people with diabetes who take insulin injections to control their diabetes say they have intentionally skipped an injection, with one-fifth of them reporting that they do so "sometimes" or "often," according to a study being published this month in Diabetes Care.

27 Jan 2010

Musculoskeletal injuries more prevalent among female athletes

Female athletes experience dramatically higher rates of specific musculoskeletal injuries and medical conditions compared to male athletes, according to exercise physiologist Vicki Harber in the Faculty of Physical Education and Recreation at the University of Alberta.

27 Jan 2010

Cinergy Health creates five steps to reduce childhood obesity

Cinergy Health, a nationwide health insurance agency providing guaranteed issue and short term major medical insurance programs, responds to the alarming rise in childhood obesity. One in three children in America is overweight or obese and one out of every five teenagers has a cholesterol level that increases the risk of heart disease.

27 Jan 2010

DuPont announces fourth quarter 2009 earnings

DuPont's fourth-quarter 2009 earnings were $.48 per share, compared to a fourth-quarter 2008 loss of $.70 per share. Excluding significant items, fourth-quarter 2009 earnings were $.44 per share versus a $.28 per share loss in the prior year (see Schedule B.).

27 Jan 2010

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations.

27 Jan 2010

Burnham renamed to honor T. Denny Sanford's support

Burnham Institute for Medical Research (Burnham) announced today that philanthropist T. Denny Sanford has pledged $50 million to support and further expand and accelerate the Institute's leading-edge medical research. To honor Sanford, Burnham, has been renamed the Sanford-Burnham Medical Research Institute. This is the second gift Sanford has made to Burnham. In 2007, he directed $20 million through Sanford Health to create the Sanford Children's Health Research Center at Burnham.

27 Jan 2010

Update on Cardium Therapeutics' plans for commercial development of Generx

Cardium Therapeutics reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.

27 Jan 2010

H.N. and Frances C. Berger Foundation donates $1M for Haiti relief efforts

The H.N. and Frances C. Berger Foundation is committing $1-million for emergency and medical supplies to assist relief efforts in Haiti. The donation will be made to Eisenhower Medical Center, which is currently engaged in the relief effort through Eisenhower's Emergency Physician Raul Ruiz, MD, MPP, MPH. Dr. Ruiz will facilitate the donation to Samaritan's Purse®, a non-profit organization that has worked in Haiti for more than 30 years.

27 Jan 2010

Asan Medical Center, Chemizon enter into multi-year research collaboration agreement

Asan Medical Center and Chemizon, the drug discovery division of Optomagic, Co. Ltd., announced today that they have entered into a multi-year research collaboration to discover and develop novel, small molecule oncology therapeutics.

27 Jan 2010

FDA recalls Huber infusion set needles

The U.S. Food and Drug Administration today announced a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets, manufactured by Nipro Medical Corporation for Exelint International Corporation.finf

27 Jan 2010

Invatec launches Maris Plus self-expanding peripheral stent system

Invatec, a comprehensive innovator of interventional products, today launched its latest self-expanding peripheral stent system, Maris Plus in new 6, 7 and 8mm diameters, ideal for interventions involving the superficial femoral arteries (SFA). The 9, 10 and 12mm diameters of the stent are already marketed for the iliac artery.

27 Jan 2010

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a fibromyalgia drug that improves sleep quality more than Pfizer's Lyrica would earn a 38 percent patient share in the U.S. and a 30 percent patient share in Europe due to its efficacy, safety and tolerability, and delivery.

27 Jan 2010

U.S. court decision favors Teva in generic Temodar ANDA litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Schering-Plough’s brain tumor treatment Temodar® (temozolomide). The Court found that U.S. Patent No. 5,260,291 is not enforceable due to prosecution laches and inequitable conduct.

27 Jan 2010

Microbia's beta-carotene receives 'GRAS' status for food and beverage applications

Microbia, Inc., today announced that a panel of independent experts has determined its bio-based β-carotene (beta-carotene) to be GRAS (Generally Recognized As Safe) for both food and beverage applications.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Quest Diagnostics expands share repurchase program

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $750 million.

From Quest Diagnostics 27 Jan 2010

Resveratrol supplements may offer potential benefits for cancer patients

For years, consumers and natural health advocates have been convinced of the benefits of resveratrol, the healthy by-product of red-wine grapes, but recently, the National Cancer Institute decided it was time to investigate further.

27 Jan 2010

Gates annual letter addresses importance of innovation for global health, agriculture

In his second annual letter, Bill Gates reflects on the Bill & Melinda Gates Foundation's work and the importance innovation will play in overcoming some of the world's greatest challenges, including in global health and agriculture, the Associated Press reports. "Gates says the foundation currently is backing 30 areas of innovation including online learning, teacher improvement, malaria vaccine development, HIV prevention, and genetically modified seeds," according to the news service (Gordon Blankinship, 1/25).

27 Jan 2010

New contract gives U.S. Naval hospitals access to ECRI Institute's medical equipment advisory service and product safety alerts

ECRI Institute®(www.ecri.org), an independent nonprofit that researches the best approaches to improving patient care, announces a new contract, awarded by the U.S. Navy to ECRI Institute, to offer its comprehensive advisory service for managing medical equipment procurement, maintenance, and safety to all U.S. Naval hospitals and medical centers worldwide.

27 Jan 2010

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.

27 Jan 2010

Medical News

Potential risk factors in skipping insulin injections

Musculoskeletal injuries more prevalent among female athletes

Cinergy Health creates five steps to reduce childhood obesity

DuPont announces fourth quarter 2009 earnings

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

Burnham renamed to honor T. Denny Sanford's support

Update on Cardium Therapeutics' plans for commercial development of Generx

H.N. and Frances C. Berger Foundation donates $1M for Haiti relief efforts

Asan Medical Center, Chemizon enter into multi-year research collaboration agreement

FDA recalls Huber infusion set needles

Invatec launches Maris Plus self-expanding peripheral stent system

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

U.S. court decision favors Teva in generic Temodar ANDA litigation

Microbia's beta-carotene receives 'GRAS' status for food and beverage applications

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Quest Diagnostics expands share repurchase program

Resveratrol supplements may offer potential benefits for cancer patients

Gates annual letter addresses importance of innovation for global health, agriculture

New contract gives U.S. Naval hospitals access to ECRI Institute's medical equipment advisory service and product safety alerts

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News